Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery
Christine Park(Duke University), Scott Floyd(Duke University), Carey K. Anders(Duke University), W Giles(Duke Medical Center), Evan Buckley, Amanda E.D. Van Swearingen(Duke Cancer Institute), John P. Kirkpatrick(Duke University), James E. Herndon(Duke University)
Cited by 12
Related Papers
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
|International Journal of Radiation Oncology*Biology*Physics|2009|984
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917